Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: Study protocol for a randomized controlled trial

BACKGROUND: The presence of pulmonary hypertension (PH) severely aggravates the clinical course of heart failure with preserved ejection fraction (HFPEF) resulting in substantial morbidity and mortality. So far, neither established heart failure therapies nor pulmonary vasodilators have proven to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascherbauer, Julia, Grünig, Ekkehard, Halank, Michael, Hohenforst-Schmidt, Wolfgang, Kammerlander, Andreas A., Pretsch, Ingrid, Steringer-Mascherbauer, Regina, Ulrich, Silvia, Lang, Irene M., Wargenau, Manfred, Frey, Reiner, Bonderman, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161763/
https://www.ncbi.nlm.nih.gov/pubmed/27590259
http://dx.doi.org/10.1007/s00508-016-1068-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161763/
https://www.ncbi.nlm.nih.gov/pubmed/27590259
http://dx.doi.org/10.1007/s00508-016-1068-8

Ejemplares similares